|101.26||+2.18||+2.20%||Vol 6.17M||1Y Perf -16.29%|
|Mar 31st, 2023 16:03 DELAYED|
|- -||-0.71 -0.70%|
|Target Price||118.53||Analyst Rating||Strong Buy 1.41|
|Potential %||17.06||Finscreener Ranking||★★+ 48.03|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 48.43|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 58.26|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★★ 46.50|
|Price Range Ratio 52W %||25.75||Earnings Rating||Neutral|
|Market Cap||175.98B||Earnings Date||19th Apr 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||19th Apr 2023|
|Estimated EPS Next Report||0.98|
|EPS Growth Next 5 Years %||5.10|
|Avg. Weekly Volume||5.17M|
|Avg. Monthly Volume||5.38M|
|Avg. Quarterly Volume||5.03M|
Abbott Laboratories (NYSE: ABT) stock closed at 101.26 per share at the end of the most recent trading day (a 2.2% change compared to the prior day closing price) with a volume of 6.17M shares and market capitalization of 175.98B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.
The one-year performance of Abbott Laboratories stock is -16.29%, while year-to-date (YTD) performance is -7.77%. ABT stock has a five-year performance of 68.99%. Its 52-week range is between 93.25 and 124.36, which gives ABT stock a 52-week price range ratio of 25.75%
Abbott Laboratories currently has a PE ratio of 25.40, a price-to-book (PB) ratio of 5.49, a price-to-sale (PS) ratio of 5.83, a price to cashflow ratio of 19.30, a PEG ratio of 2.32, a ROA of 11.66%, a ROC of 15.73% and a ROE of 24.34%. The company’s profit margin is 17.58%, its EBITDA margin is 29.30%, and its revenue ttm is $33.56 Billion , which makes it $19.25 revenue per share.
Of the last four earnings reports from Abbott Laboratories, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.98 for the next earnings report. Abbott Laboratories’s next earnings report date is 19th Apr 2023.
The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.41), with a target price of $118.53, which is +17.06% compared to the current price. The earnings rating for Abbott Laboratories stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Abbott Laboratories has a dividend yield of 1.82% with a dividend per share of $2.04 and a payout ratio of 45.00%.
Abbott Laboratories has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.22, ATR14 : 1.87, CCI20 : 134.49, Chaikin Money Flow : -0.03, MACD : -1.23, Money Flow Index : 62.57, ROC : 3.54, RSI : 53.72, STOCH (14,3) : 96.98, STOCH RSI : 1.00, UO : 59.79, Williams %R : -3.02), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Sold 679 shares of value $68 375 ), Daniel Gesua Sive Salvadori (Sold 1 085 shares of value $109 260 ), Daniel J. Starks (Sold 150 000 shares of value $15 990 972 ), Fernando Mateus (Sold 2 457 shares of value $267 943 ), Gregory A. Ahlberg (Sold 1 317 shares of value $132 622 ), Hubert L. Allen (Sold 1 069 shares of value $107 648 ), Jared L. Watkin (Sold 1 198 shares of value $120 639 ), John F. Ginascol (Sold 11 943 shares of value $1 330 480 ), Joseph J. Manning (Option Excercise at a value of $2 043 110), Joseph J. Manning (Sold 51 245 shares of value $5 421 781 ), Julie L. Tyler (Sold 1 038 shares of value $107 310 ), Lisa D. Earnhardt (Sold 943 shares of value $94 960 ), Mary K. Moreland (Sold 717 shares of value $72 252 ), Michael D. Dale (Sold 1 209 shares of value $121 746 ), Randel W. Woodgrift (Option Excercise at a value of $1 065 600), Randel W. Woodgrift (Sold 25 032 shares of value $2 816 025 ), Robert B. Ford (Option Excercise at a value of $4 121 870), Robert B. Ford (Sold 102 425 shares of value $10 765 154 ), Robert E. Funck (Sold 1 264 shares of value $127 285 ), Sammy Karam (Sold 4 200 shares of value $456 750 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
CEO: Robert B. Ford
Telephone: +1 224 667-6100
Address: 100 Abbott Park Road, Abbott Park 60064-6400, IL, US
Number of employees: 109 000
Thu, 09 Mar 2023 04:10 GMT Analysts Conflicted on These Healthcare Names: Abbott Labs (ABT), BioMarin Pharmaceutical (BMRN) and Marinus (MRNS)- TipRanks. All rights reserved.
Tue, 07 Mar 2023 12:20 GMT Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Tenax Therapeutics (TENX) and Day One Biopharmaceuticals (DAWN)- TipRanks. All rights reserved.
Mon, 06 Mar 2023 13:35 GMT Abbott Labs (ABT) Gets a Buy from BTIG- TipRanks. All rights reserved.
Mon, 06 Mar 2023 11:50 GMT Analysts Top Healthcare Picks: Abbott Labs (ABT), Eli Lilly & Co (LLY)- TipRanks. All rights reserved.
Thu, 09 Feb 2023 10:10 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Abbott Labs (ABT) and Phibro Animal Health (PAHC)- TipRanks. All rights reserved.
Thu, 09 Feb 2023 07:10 GMT Abbott (ABT) Trying to Lift Sales With $890M Buyout- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.